A record of 1320 suspect, deferasirox-related, patient deaths reported in 2009: Insufficient toxicity testing, low efficacy and lack of transparency may endanger the lives of iron loaded patients

Hemoglobin

Volumn 35, Issue 3, 2011, Pages 301-311

  Kontoghiorghes, George J ^a  

^a Postgraduate Research Institute of Science Technology Environment and Medicine Limassol   (Cyprus)

Author keywords

[No Author keywords available]

Indexed keywords

8 QUINOLINOL; CHELATING AGENT; COPPER; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERRITIN; IRON; MALTOL; ROSIGLITAZONE; ZINC;

AGRANULOCYTOSIS; BETA THALASSEMIA INTERMEDIA; CHELATION THERAPY; COPPER BLOOD LEVEL; DRUG ABSORPTION; DRUG COST; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; ENTEROHEPATIC CIRCULATION; FERRITIN BLOOD LEVEL; GASTROINTESTINAL TRACT; GENETIC DISORDER; HEART FAILURE; HEMOCHROMATOSIS; HUMAN; IRON ABSORPTION; IRON BLOOD LEVEL; IRON CHELATION; IRON INTAKE; IRON OVERLOAD; KIDNEY FAILURE; LETTER; LIVER FAILURE; LIVER LEVEL; MARKETING; METABOLISM; MORBIDITY; MORTALITY; MULTIPLE ORGAN FAILURE; PANCYTOPENIA; REGULATORY MECHANISM; RISK ASSESSMENT; THALASSEMIA; TOXICITY; UNSPECIFIED SIDE EFFECT; ZINC BLOOD LEVEL;

BENZOIC ACIDS; DRUG TOXICITY; ETHICS, MEDICAL; ETHICS, RESEARCH; HUMANS; IRON OVERLOAD; TRIAZOLES;

EID: 79957492233     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.3109/03630269.2011.576906     Document Type: Letter

References (43)

1. Nick H. Letter to the Editor. Iron chelation therapy in hereditary hemochromatosis and thalassemia intermedia: regulatory and non regulatory mechanisms of increased iron absorption [Kontoghiorghes GJ, Spyrou A, Kolganou A. Hemoglobin. 2010;34(3);251-264] Hemoglobin. 2011;35(2): 175-179
2. Kontoghiorghes GJ. Deferasirox: uncertain future following renal failure fatalities, agranulocytosis and other toxicities. Expert Opin Drug Saf. 2007;6(3): 236-239
3. Kontoghiorghes GJ. Ethical issues and risk/benefit assessment on iron chelation therapy: Advances with deferiprone/deferoxamine combination and concerns on deferasirox's safety, efficacy and costs. Hemoglobin. 2008;32(1-2): 1-15 (Pubitemid 351264512)
4. Maggio A. Light and shadows in the iron chelation treatment of haematological diseases. Br J Haematol. 2007;138(3): 407-421 (Pubitemid 47063024)
5. Anonymous. Deferasirox: for iron overload: only a third-line option. Prescrire Int. 2007;16(91): 196
6. Angelucci E, Barosi G, Camaschella C, et al. Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica. 2008;93(5): 741-752 (Pubitemid 351669315)
7. Kontoghiorghes GJ. Response to the Letter to the Editor: Transparency and access to full information for the fatal or serious toxicity risks, low efficacy and high price of deferasirox, could increase the prospect of improved iron chelation therapy worldwide. Hemoglobin. 2008;32(6): 608-615
8. Kontoghiorghes GJ, Kolnagou A. Molecular factors and mechanisms affecting iron and other metal excretion or absorption in health and disease. The role of natural and synthetic chelators. Curr Med Chem. 2005;12(23): 2695-2709 (Pubitemid 41601568)
9. Kontoghiorghes GJ, Spyrou A, Kolganou A. Iron chelation therapy in hereditary hemochromatosis and thalassemia intermedia: regulatory and non regulatory mechanisms of increased iron absorption. Hemoglobin. 2010;34(3);251-264
10. Kontoghiorghes GJ. Chelators affecting iron absorption in mice. Arzneimittelforschung. 1990;40(12): 1332-1335
11. Stobie S, Tyberg J, Matsui D, et al. Comparison of the pharmacokinetics of 1,2-dimethyl-3- hydroxypyrid-4-one (L1) in healthy volunteers, with and without co-administration of ferrous sulfate, to thalassemia patients. Int J Clin Pharmacol Ther Toxicol. 1993;31(12): 602-605 (Pubitemid 23355442)
12. Dresow B, Fischer R, Nielsen P, Gabbe EE, Piga A. Effect of oral iron chelator L1 in iron absorption in man. Ann NY Acad Sci. 1998;850: 466-468 (Pubitemid 28369806)
13. Gomez HF, McClafferty HH, Flory D, Brent J, Dart RC. Prevention of gastrointestinal iron absorption by chelation from an orally administered premixed deferoxamine/charcoal slurry. Ann Emerg Med. 1997;30(5): 587-592 (Pubitemid 27469161)
14. Nick H, Wong A, Acklin P, et al. ICL670A: preclinical profile. Adv Exp Med Biol. 2002;509: 185-203 (Pubitemid 37526718)
15. Kontoghiorghes GJ. Do we need more iron chelating drugs? Lancet 2003;362(9382): 495-496 (Pubitemid 36999722)
16. Bruin GJ, Faller T, Wiegand H, et al. Pharmacokinetics, distribution, metabolism, and excretion of deferasirox and its iron complex in rats. Drug Metab Dispos. 2008;36(12): 2523-2538
17. Anonymous. Exjade (deferasirox) tablets for oral suspension. Prescribing information. Novartis Pharmaceutical Corporation USA (NDA 21-882).October, 2006; 1-12 Changes to the warnings and adverse reactions sections (www.fda.gov) 2006 and 2007
18. Kontoghiorghes GJ, Barr J, Baillod RA. Studies of aluminium mobilisation in renal dialysis patients using the oral chelator 1,2-dimethyl-3-hydroxypyrid- 4-one. Arzneimittelforschung. 1994;44(4): 522-526 (Pubitemid 24122314)
19. Kontoghiorghes GJ, Sheppard L, Barr J, Baillod R. Aluminium mobilisation in renal dialysis patients using the oral chelator 1,2-dimethyl-3-hydroxypyrid- 4-one (L1).Drugs Today (Barc).1992;28 (Suppl. A): 183-187 (Pubitemid 23038106)
20. Liu P, Yao YN,Wu SD, Dong HJ, Feng GC, Yuan XY. The efficacy of deferiprone on tissues aluminum removal and copper, zinc, manganese level in rabbits. J Inorg Biochem. 2005;99(8): 1733-1737 (Pubitemid 41039933)
21. Malluche HH, Smith AJ, Abreo K, Faugere MC. The use of deferoxamine in the management of aluminium accumulation in bone in patients with renal failure. N Engl JMed. 1984;311(3): 140-144 (Pubitemid 14092902)
22. Djaldetti M, Fishman P, Notti I, Bessler H. The effect of tetracycline administration on iron absorption in mice. Biomedicine. 1981;35(5): 150-152 (Pubitemid 12174174)
23. Hurrell RF, Reddy M, Cook JD. Inhibition of non-haem iron absorption in man by polyphenoliccontaining beverages. Br J Nutr. 1999;81(4): 289-295 (Pubitemid 29248500)
24. Shakeri-Nejad K, Stahlmann R. Drug interactions during therapy with three major groups ofantimicrobial agents. Expert Opin Pharmacother. 2006;7(6): 639-651
25. Sandberg AS, Brune M, Carlsson NG, Hallberg L, Skoglund E, Rossander-Hulthén L. Inositol phosphates with different numbers of phosphate groups influence iron absorption in humans. Am J Clin Nutr. 1999;70(2): 240-246 (Pubitemid 29347570)
26. Rossander-Hultén L, Brune M, Sandström B, Lönnerdal B, Hallberg L. Competitive inhibition of iron absorption by manganese and zinc in humans. Am J Clin Nutr. 1991;54(1): 152-156 (Pubitemid 21898931)
27. Tuntawiroon M, Sritongkul N, Brune M, et al. Dose-dependent inhibitory effect of phenolic compounds in foods on nonheme-iron absorption in men. Am J Clin Nutr. 1991;53(2): 554-557 (Pubitemid 121000868)
28. Glahn RP, Wortley GM, South PK, Miller DD. Inhibition of iron uptake by phytic acid, tannic acid, and ZnCl2: studies using an in vitro digestion/Caco-2 cell model. J Agric Food Chem. 2002;50(2): 390-395 (Pubitemid 34052788)
29. Kontoghiorghes GJ. Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities. Expert Opin Drug Saf. 2010;9(4): 633-641
30. Anonymous. Fatal adverse drug events. ISMP Medication Safety Alert. 2010;15(12): 1-3
31. Kontoghiorghes GJ, Kolnagou A, Peng CT, Shah SV, Aessopos A. Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases. Expert Opin Drug Saf. 2010;9(2): 201-206
32. Vlachaki E, Chatzinikolaou K, Bekiari E, Klonizakis F, Tsapas A. Is deferasirox implicated in multiple organ failure in a patient with homozygous β-thalassemia? Angiology. 2011;(Epub ahead of print).
33. Phatak P, Brissot P, Wurster M, et al. A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis. Hepatology. 2010; (Epub ahead of print) doi: 101002/hep.23879
34. Kontoghiorghes GJ, Eracleous E, Economides Ch, Kolnagou A. Advances in iron overload therapies. Prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NAll and their combinations. Curr Med Chem. 2005;12(23): 2663-2681 (Pubitemid 41601566)
35. Kolnagou A, Economides Ch, Eracleous E, Kontoghiorghes GJ. Long-term comparative studiesin thalassemia patients treated with deferoxamine or deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols. Hemoglobin. 2008;32(1-2): 41-47 (Pubitemid 351264511)
36. Kolnagou A, Kleanthous M, Kontoghiorghes GJ. Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/ deferoxamine combination and their maintenance thereafter by deferiprone monotherapy. Eur J Haematol. 2010;85(5): 430-438
37. Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol. 2010;148(3): 466-475
38. Tefler P, Goen PG, Christou S, et al. Survival of medically treated thalassaemia patients in Cyprus.Trends and risk factors over the period 1980-2004 Haematologica. 2006;91(9): 1187-1192 (Pubitemid 44408428)
39. Pennell DJ, Porter JB, Cappellini MD, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia. Blood. 2010;115(12): 2364-2371
40. Wood JC, Kang BP, Thompson A, et al. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood. 2010;116(4): 537-543
41. Pepe A, Meloni A, Capra M, et al. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Haematologica. 2011;96(1): 41-47
42. Wood JC, Glynos T, Thompson A, et al. Relationship between LPI, LIC, and cardiac response in a deferasirox monotherapy trial. Haematologica. 2011;(Epub ahead of print).
43. Kontoghiorghes GJ. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients. Hemoglobin. 2009;33(5): 332-338